Burning mouth syndrome (BMS) is a syndrome associated with chronic continuous pain that commonly affects middle-or old-aged women who have hormonal changes or psychological disorders. This syndrome has been stated to have a multifactorial origin. Presently, they are classified into two types, namely, "primary" (idiopathic) and "secondary" (resultant of an identified precipitating factor) BMS. Owing to the various overlapping oral mucosal pathologies, BMS tends to be complicated to diagnose. BMS treatment is still not satisfactory, and there is no definitive cure. There is need of more research to validate the association that exists among BMS and systemic disorders and to consider probable pathogenic mechanisms that involve nerve damage. The present paper deals with several aspects of BMS and provides details regarding a multidisciplinary approach for patient management.
Introduction
Burning mouth syndrome (BMS) is a condition characterized by chronic pain associated with burning, itching and/or stinging in the oral cavity with the absence of any type of organic disease. It is an ill-defined condition that affects mostly middle-aged women. The conditions last for a minimum of 4-6 months and most often is seen involving the tongue with or without involvement to the lips and oral mucosa. [1, 2] BMS can be associated with dysgeusia and xerostomia. BMS was first diagnosed as a condition during the mid -19 th century and by the early 20 th century the condition was termed as glossodynia by Butlin and Oppenheim. [1] With various researchers presenting various articles on BMS over the period of years, it was termed by different names such as glossopyrosis, oral dysesthesia, sore tongue, stomatodynia, and stomatopyrosis. In 2004, it was first categorized as a distinctive disease, in 2004, by the International Headache Society (IHS). [3] Lamey and Lamb, 1988; Bergdahl et al., 1995b ; Jerlang, 1997 [4] have all stated that BMS deteriorate the quality of life and patient's lifestyle due to psychological dysfunction.
Definition
The International Association for the Study of Pain and IHS defines it as a "distinctive nosological entity," including "all forms of burning sensation in the mouth, including complaints described as stinging sensation or pain, in association with an oral mucosa that appears clinically normal in the absence of local or systemic diseases or alterations." [5] 
Epidemiology
As it is aware that there is a lack of appropriate and ideal classification system, diagnostic criteria, and knowledge among oral health-care professionals regarding BMS, it is hard to validate and authenticate the exact prevalence of the disease.
International estimates of prevalence vary from 0.7% to 0.15%. [3] BMS basically affects middle-and elderly-aged individuals with an average age range of 38-78 years. [4] This syndrome is stated to primarily affect women in the age group 50-60 years, especially prone toward women in their postmenopausal stage where the prevalence increases to about 13%, usually BMS first occurs 3-12 years after the menopause and rarely before the age of 30. [6] [7] [8] Classification [ Table 1] Scala et al. [4] classified BMS into two clinical forms
• Primary or essential/idiopathic BMS: This type involves the absence to identify any local or systemic causes that give way to neuropathological cause [4] • Secondary' BMS: It is a condition that results from local or systemic pathological conditions at risk to etiology directly. A variety of conditions may lead to "secondary" BMS. [4] These include mucosal diseases such as lichen planus, candidiasis, vitamin or nutritional deficiencies, psychosocial stress, diabetes, contact allergies, galvanism, parafunctional habits, cranial nerve injuries, and medication side effects. [4] Cerchiari classified BMS according to the associated risk factors [9] • Idiopathic • Psychogenic • Local and systemic. [4, 6, [10] [11] [12] [13] [14] [15] [16] A. Physical [4, 6, [10] [11] [12] [13] [14] [15] [16] • Anxiety • Depression • Compulsive disorders • Stress • Cancerophobia. 5. Medications [17] • Antihypertensive • Angiotensin converting enzyme inhibitors such as captopril, enalapril, and lisinopril • Angiotensin receptor antagonist-like eprosartan and candesartan • Antihistamines • Antidepressants -Fluoxetine, sertraline, venlafaxine • Neuroleptics [18, 19] • Another theory states that the sensory dysfunction associated with small and/or large fiber neuropathy is present in BMS. This has been further proven by the immunohistochemical and microscopic studies which depicted that axonal degeneration of epithelial and subpapillary nerve fibers are present in the epithelium of the oral mucosa in patients affected by BMS [20] • Another theory states that there is a reduction in the nigrostriatal dopaminergic system. This is explained to be associated with alteration in the modulation of nociceptive processing theory which, in turn, reduces central pain suppression in BMS individuals [21, 22] • It is observed that there is a loss in the balance of autonomic innervation and disturbance in oral blood flow. [23, 24] Clinical Features BMS has been described to have varied chronic oral symptoms. These symptoms characteristically show increase in their intensity at the end of each day but is never observed to have any interference with sleep. Two specific clinical features are been given to diagnose a condition as:
Etiopathogenesis

Local factors
BMS
• A "symptomatic triad" including the unrelenting pain of the oral mucosa, dysgeusia, and xerostomia
• "No signs" of lesions or other detectable changes in the oral mucosa, even in the painful areas. [25, 26] The pain in the mucosa lining the oral cavity may be often described by the patient as burning, itching, or an anesthetized feeling associated with dysgeusia. The secondary symptoms, which may or may not be presented by the patient, are dry mouth, thirst, headache, pain in the TMJ, pain in masticatory, suprahyoid muscles extending toward shoulder and neck region. [27] Dorsal tongue, palate, lips, and gingival tissues either individually or in combination are usually the sites of occurrence that have been observed in the available literature [ Table 2 ]. [28] 
Diagnosis
An appropriate clinical history along with a careful examination of the oral mucosa is necessary to land at a diagnosis of BMS, without the presence of other overlapping conditions. A complete assessment of quality, intensity, onset, incidence, persistence, overall time period, progression, and the location is mandatory in cases of BMS. BMS should be differentiated systematically and systemically from a variety of chronic pain conditions that could be elicited by the patient. [29] The chief clinical features in various idiopathic orofacial pain conditions have been dealt in Table 3 .
Investigations
BMSs are associated with such a wide variety of other referral to a specialist for screening and diagnosis is to be done [ Table 4 ].
Clinical tests that may be helpful
• MRI: To rule out central changes, especially if pain is unilateral, atypical or does not or does not respond to medication. [30, 31] • Salivary flows: For unstimulated and stimulated whole saliva (<1.5 ml/0.5 min, unstimulated <4.5 mg/5 min stimulated) • Salivary uptake scans: If low salivary flows and Sjögren's suspected removal of possibly offending medication including angiotensin-convening enzyme inhibitor. [30] [31] [32] 
Management
Owing to the large range of associated factors, the etiquette for BMS management is an approach for the patients should be based on a strict collaboration among different oral medicine specialists. [31] Primarily patient management involves a systematic differential diagnosis followed by discrimination between "primary" and "secondary." This is dependent on the identification of probable etiologic factors for the syndrome.
Patients with secondary BMS can fall into specific subcategories according to the identified disorders ("patient stratification"), and subsequently, they undergo appropriate therapy based on identified etiologies. The remaining cases (primary BMS) will undergo proper pain control. This [28] Pain Features • Descriptors Burning
• Intensity
Variable, weak to intense
• Pattern
Continuous, not paroxysmal
• Localization Independent of a nervous pathway
Often bilateral and symmetrical
• Paroxysmal No
• Pain during sleep Infrequent
• Other associated signs/symptoms
Dysgeusia, xerostomia, thirst sensory, chemo-sensory anomalies psychological profile may be changed systematic approach to BMS has been reported to make patient management more predictable and effective.
[31]
The available treatment options can be grouped into several major areas, and these are listed in the order of most frequent use: [31] • No treatment • Secondary BMS patients must be treated for the precipitating factors of the disorder initially • Xerostomia is managed with 7-day periods of saliva substitutes or various saliva-stimulating agents • Active stimulation of salivation can be induced using chewing gums or sweets (containing sorbitol, not sucrose), passive stimulation can be obtained by specific cholinergic drugs (sialagogues), such as pilocarpine • Gynecologist referral is a must for peri-/post-menopausal women • Administration of conjugated estrogens and medroxyprogesterone acetate can be used to relieve from the BMS symptoms • Vitamin B complex replacement therapy (pyridoxine, riboflavin, thiamine, etc.) must be administered in patients with nutritional deficiency. • Benzodiazepine -e.g., Clonazepam, chlordiazepoxide • Anticonvulsants -e.g., Gabapentin, pregabalin, topiramate • Atypical analgesic -e.g., Capsaicin • Antidepressants -e.g., Amitriptyline, imipramine, nortriptyline • Selective serotonin reuptake inhibitors -e.g., Paroxetine, sertraline • Selective norepinephrine reuptake inhibitors -e.g., Milnacipran • Antioxidant -e.g., α-lipoic acid • Antipsychotics -e.g., Amisulpride, levosulpride.
• Atypical antipsychotic -e.g., Olanzipine • Dopamine agonist -e.g., Pramipexole • Histamine 2 receptor antagonist -e.g., Lafutidine • Herbal supplement -e.g., Hypericum perforatum • Salivary stimulants -e.g., Pilocarpaine, sialor, cevimiline, and bethanechol [ Table 5 ].
Conclusion
BMS is a painful and frequently annoying condition. The precise reason of BMS often is difficult to identify and is possibly multifactorial. The etiopathogenesis of BMS is complex thereby making diagnosis and management of BMS is complicated. Further research is required for better understanding of the etiology and psychological effect. This understanding must be combined with ideal pharmacological interventions is required for appropriate management. Table 5 : To summarize efficacy and safety of the drugs used to treat the symptoms of BMS [33] [34] [35] [36] [37] [38] [39] [40] [41] Tammiala-Salonen et al. [33] Trazodone 100 mg od for 4 days followed by 100 mg every 12 h for 8 weeks
Maina et al. [32] Amisulpride 50 mg/day for 8 weeks
Maina et al. [32] Paroxetine 20 mg/day for 8 weeks
Maina et al. [32] Sertraline 50 mg/day for 8 weeks
Heckmann et al. [34] Gabapentin Initial dose of 300 mg day, increased at a rate of 300 mg every 48 h to a maximum of 2400 mg/day for 3 weeks
Petruzzi et al. [38] Capsaicin Capsaicin 0.25% via the oral route for 4 weeks
Grushka et al. [35] Systemic clonazepam
The starting dose of 0.25 mg/day increased at a rate of 0.25 mg/week, to a maximum of 3 mg/day for 8 weeks
Woda et al. [36] Topical clonazepam 0.5-1 mg, 2 or 3 times a day instructed to break up the clonazepam tablet retain saliva in the mouth during 3 min
Sardella et al. [39] Benzydamine 15 ml of benzydamine hydrochloride 0.15% as a rinse for 1 min, 3 times a day during 4 weeks
Campisi et al. [40] Sucralfate 20% suspension of sucralfate 4 times a day during 3 weeks
Femiano et al. [41] Alpha-lipoic acid 600 mg/day for 8 weeks
Gorsky et al. [27] Chlordiazepoxide 15-30 mg/day BMS: Burning mouth syndrome
